Appendix B: Sources of evidence considered by the Committee

Appendix B: Sources of evidence considered by the Committee

A. The Evidence Review Group (ERG) report for this appraisal was prepared by Southampton Health Technology Assessment Centre:

  • Jones J, Mendes D, Frampton GK et al. Aripiprazole for the treatment of schizophrenia in adolescents (aged 15–17 years), July 2010.

B. The following organisations accepted the invitation to participate in this appraisal as consultees and commentators. They were invited to comment on the draft scope, the ERG report and the appraisal consultation document (ACD). Organisations listed in I were also invited to make written submissions. Organisations listed in II and III had the opportunity to give their expert views. Organisations listed in I, II and III also have the opportunity to appeal against the final appraisal determination.

I) Manufacturer/sponsor:

  • Bristol Myers Squibb/Otsuka Pharmaceuticals

II) Professional/specialist and patient/carer groups:

  • British Association for Psychopharmacology

  • Royal College

  • Royal College and Child Health

  • Royal of Pathologists

  • Royal of Psychiatrists

III) Other consultees:

  • Betsi Cadwaladr University Health Board

  • Department of Health

  • Welsh Assembly Government

IV) Commentator organisations (did not provide written evidence and without the right of appeal):

  • Commissioning Support Appraisals Service

  • Department of Health, Social Services and Public Safety for Nothern Ireland

  • Hafal

  • Medicines and Healthcare Products Regulatory Agency

  • NHS Quality Improvement Scotland

  • AstraZeneca

  • Eli Lilly and Company

  • Cochrane Schizophrenia Group

  • National Institute for Health Research Health Technology Assessment Programme

  • Southampton Health Technology Assessment Centre

  • National Collaborating Centre for Mental Health

C. The following individuals were selected from clinical specialist and patient expert nominations from the non-manufacturer consultees and commentators. They gave their expert personal view on aripiprazole for the treatment of schizophrenia in people aged 15 to 17 years by attending the initial Committee discussion and providing written evidence to the Committee. They were also invited to comment on the ACD.

  • Clare Lamb, Consultant Psychiatrist, nominated by Welsh Assembly Government – clinical specialist

  • Tim McDougall, Nurse Consultant, nominated by Royal College of Nursing – clinical specialist

  • Clive Travis – patient expert

  • Janey Antoniou (written statement only, unable to attend the meeting) – patient expert

    We would like to offer our condolences to Janey Antoniou's family; sadly, Janey died during the development of this technology appraisal. Janey was a great help during this appraisal and will be sadly missed by her family and colleagues alike.

D. Representatives from the following manufacturers attended Committee meetings. They contributed only when asked by the Committee chair to clarify specific issues and comment on factual accuracy. They were also invited to comment on the ACD.

  • Bristol Myers Squibb and Otsuka Pharmaceuticals

  • National Institute for Health and Care Excellence (NICE)